Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Suaya JA"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Cardiopulmonary Rehabilitation & Prevention; 2008 Nov-Dec, Vol. 28 Issue 6, p380-385, 6p
Publikováno v:
Circulation; 10/9/2007, Vol. 116 Issue 15, p1653-1662, 10p
Publikováno v:
In Value in Health 2002 5(3):257-257
Autor:
Hsiao A; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA. Electronic address: Amber.Hyman@kp.org., Lewis N; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA., Hansen J; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA., Timbol J; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA., Suaya JA; Heller School, Brandeis University, Waltham, MA, USA., Alexander-Parrish R; Pfizer Vaccine Medicines Development & Scientific Clinical Affairs, Collegeville, PA, USA., Grant LR; Pfizer Vaccine Medicines Development & Scientific Clinical Affairs, Collegeville, PA, USA., Gessner BD; Pfizer Vaccine Medicines Development & Scientific Clinical Affairs, Collegeville, PA, USA., Klein NP; Kaiser Permanente Vaccine Study Center, Oakland, CA, USA.
Publikováno v:
Vaccine [Vaccine] 2025 Jan 12; Vol. 44, pp. 126543. Date of Electronic Publication: 2024 Dec 04.
Autor:
Bollaerts K; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Fletcher MA; Pfizer, Inc, Emerging Markets Medical Affairs, Paris, France., Suaya JA; Pfizer, Inc, Vaccines Medical Development and Scientific/Clinical Affairs, New York, New York, USA., Hanquet G; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Baay M; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Gessner BD; Pfizer, Inc, Scientific Affairs, Collegeville, Pennsylvania, USA.
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Apr 28; Vol. 74 (8), pp. 1362-1371.
Autor:
Suaya JA; Vaccines Medical Development and Medical/Scientific Affairs, Pfizer Inc, 235 E 42nd St, New York, NY 10017. Email: JSuaya@brandeis.edu., Tilahun E, Harrison V, McLaughlin JM, Chilson E, Vietri J, Swerdlow DL, Gessner BD, Isturiz RE
Publikováno v:
The American journal of managed care [Am J Manag Care] 2021 Aug 01; Vol. 27 (8), pp. e261-e268. Date of Electronic Publication: 2021 Aug 01.
Autor:
Glick HA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Miyazaki T; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.; Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Hirano K; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan., Gonzalez E; Vaccines Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA., Jodar L; Vaccines Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA., Gessner BD; Vaccines Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA., Isturiz RE; Vaccines Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA., Arguedas A; Vaccines Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA., Kohno S; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan., Suaya JA; Vaccines Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA.
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Jul 15; Vol. 73 (2), pp. 283-290.
Autor:
Dion SB; Pfizer Canada ULC, Kirkland, QC, Canada. Electronic address: Stephane.Dion@pfizer.com., Major M; Pfizer Canada ULC, Kirkland, QC, Canada. Electronic address: Maria.Major@pfizer.com., Gabriela Grajales A; Pfizer Canada ULC, Kirkland, QC, Canada. Electronic address: AnaGabriela.Grajales@pfizer.com., Nepal RM; Pfizer Canada ULC, Kirkland, QC, Canada. Electronic address: Rajeev.Nepal@pfizer.com., Cane A; Pfizer Inc, Collegeville, PA, USA. Electronic address: Alejandro.Cane@pfizer.com., Gessner B; Pfizer Inc, Collegeville, PA, USA. Electronic address: Bradford.Gessner@pfizer.com., Vojicic J; Pfizer Canada ULC, Kirkland, QC, Canada. Electronic address: Jelena.vojicic@pfizer.com., Suaya JA; Pfizer Inc, New York, NY, USA. Electronic address: Jose.A.Suaya@pfizer.com.
Publikováno v:
Vaccine [Vaccine] 2021 May 21; Vol. 39 (22), pp. 3007-3017. Date of Electronic Publication: 2021 Apr 03.